A Study to Evaluate the Denosumab in Healthy Adults

Healthy Adults Clinical Trial

Official title:

A Randomized, Double-blind, Parallel-group, Placebo-controlled, Single-dose Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Denosumab Injection Administered Subcutaneously to Healthy Adults in China

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03427853
• Other study ID #: LY06006
• Status: Recruiting
• Phase: Phase 1
• First received: January 31, 2018
• Last updated: February 8, 2018
• Start date: January 10, 2018
• Est. completion date: December 28, 2019

Study information

• Verified date: February 2018
• Source: Luye Pharma Group Ltd.
• Contact: Yi Fang, MD
• Phone: 8610-8832666
• Email: fygk7000[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, parallel-group, placebo-controlled, single-dose escalation Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of denosumab injection administered subcutaneously to healthy adults in China

Description:

This is a randomized, double-blind, parallel-group, placebo-controlled, single-dose escalation Phase I study in healthy adults in China, conducted in one center.

The objectives are to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of denosumab injection (code name:LY06006).

Subjects would be sequentially enrolled in one of three cohorts. Eight subjects in the first cohort would receive a single 18 mg subcutaneous injection of LY06006. If the safety and tolerability were confirmed at Day 56, the other 16 subjects would be enrolled in the second cohort to receive a single 60 mg subcutaneous injection of LY06006. If the safety and tolerability were confirmed at Day 56 in 60-mg group, the last 8 subjects would be enrolled in the third cohort to receive a single 120 mg subcutaneous injection of LY06006.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: December 28, 2019
• Est. primary completion date: December 28, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Signed ICF and complied with ICF requirement and restrictions

• Healthy male and female, 18=age=65

• In screening visit, male body weight=50kg,female body weight=45kg,and 19.0=BMI=24.0 kg/m2;

• At screening visit: physical examination, vital signs, laboratory tests, electrocardiogram, chest X-ray examination, abdominal CT examination are normal or abnormal but no clinical significance confirmed by investigators;

• During the study period and within 12 months after the study drug administration, the subjects and partners agreed to use reliable contraceptive measures

Exclusion Criteria:

• Pregnant or lactating women;

• Fertility plan within one year;

• The subject has a history of hypersensitivity or allergy to LY06006 or any of its excipients;or allergy to any drug, food and pollen, or IGE test is positive.

• Subjects are suffering from or have had osteomyelitis or osteonecrosis of the Jaw, or plan to have invasive dental or maxillofacial surgery during the study, or dental or oral surgery wounds unhealed;

• Have fractures in past six months;

• Active respiratory, digestive, urinary, reproductive or skin infections;

• Have oncology family history ;

• Have mental illness history;

• In screening visit: Chest X-ray, abdominal CT indicated clinical significance,for example: tuberculosis, inflammation, et al;

• PPD test positive with 48-72 hrs induration reading=5mm;

• Blood chemistry:ALT or AST >1.5 ULN,Cr>1.0 ULN;Blood routine:WBC<0.8 LLN or>1.2 ULN;NE<0.8 LLN;PLT<0.8 LLN;HGB<0.8LLN;

• Suffering from or have had the following diseases affecting the bone metabolism:

malignant tumors (including myeloma), hypoparathyroidism / hyperthyroidism, hypothyroidism, acromegaly, cushing's syndrome, hypopituitarism, severe chronic obstructive pulmonary disease, rheumatoid arthritis, osteomalacia et al;

• The medicines that may affect bone turnover are used before randomization or planned to use in the study period , including but not limited : denosumab, bisphosphonates or fluorides were used in past 12 months; contraceptives with hormone,hormone replacement therapy(tibolone?hormone?selective estrogen receptor modulators)aromatase inhibitors, calcitonin, strontium salt, parathyroid hormone (or derivative), vitamin D supplement,anabolic steroids, systemic glucocorticoids, calcitriol or analogues, diuretics, anticonvulsant drugs;inhalation or local use of glucocorticoids within 2 weeks

• Significant changes in physical activity in 6 months before randomization; or have been playing strenuous sports, or plan to play strenuous sports during the study period.

• Any of HBsAg, HCV-Ab, Anti-HIV, TP-Ab is positive;

• Hypocalcemia or hypercalcemia,or serum calcium calibrated by serum albumin is not within the normal range

• The average daily smoking amount is more than 5 cigarettes per day during three months before randomization, or smoking can't be prohibited during the study period;

• Alcohol abuse or drank more than 28 units / week of alcohol((1 unit =350ml beer, 45ml spirits or 150ml Wine), or alcohol breath test is positive;

• History of drug dependency or drug abuse, or urine drug screening test is positive;

• Donated whole blood, blood component, or massive hemorrhage (>400ml)three months before randomization.

• Use of any vaccines in 6 months of initiation of study therapy

• participation in another clinical trial within 3 months prior to enrollment

• Had Blood faint and acupuncture syncope history;

Related Conditions & MeSH terms

• Healthy Adults

Intervention

Drug:
• LY06006
LY06006 18mg, 60mg, 120mg subcutaneous injection
• Placebos
Placebo subcutaneous injection

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing	Xicheng District

Sponsors (2)

Lead Sponsor	Collaborator
Luye Pharma Group Ltd.	Shangdong Boan Biotechnology Co Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with treatment related adverse events	Number of patients with treatment related adverse events assessed by change from baseline	56 days
Primary	Number of patients with abnormal laboratory values	Number of patients with abnormal laboratory values assessed by change from baseline	56 days
Secondary	Maximum plasma concentration (Cmax)		56 days
Secondary	Area under the Curve (AUC)		56 days
Secondary	Number of patients with anti drug antibodies		56 days